ID   S22A6_HUMAN             Reviewed;         563 AA.
AC   Q4U2R8; A8MY93; B2D0R6; O95187; O95742; Q7LDA0; Q8N192; Q9NQA6;
AC   Q9NQC2; Q9UBG6; Q9UEQ8;
DT   18-MAR-2008, integrated into UniProtKB/Swiss-Prot.
DT   19-JUL-2005, sequence version 1.
DT   10-MAY-2017, entry version 125.
DE   RecName: Full=Solute carrier family 22 member 6;
DE   AltName: Full=Organic anion transporter 1;
DE            Short=hOAT1;
DE   AltName: Full=PAH transporter;
DE            Short=hPAHT;
DE   AltName: Full=Renal organic anion transporter 1;
DE            Short=hROAT1;
GN   Name=SLC22A6; Synonyms=OAT1, PAHT;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND FUNCTION.
RX   PubMed=9762842; DOI=10.1159/000025863;
RA   Reid G., Wolff N.A., Dautzenberg F.M., Burckhardt G.;
RT   "Cloning of a human renal p-aminohippurate transporter, hROAT1.";
RL   Kidney Blood Press. Res. 21:233-237(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), TISSUE SPECIFICITY, AND
RP   FUNCTION.
RC   TISSUE=Kidney;
RX   PubMed=9887087;
RA   Hosoyamada M., Sekine T., Kanai Y., Endou H.;
RT   "Molecular cloning and functional expression of a multispecific
RT   organic anion transporter from human kidney.";
RL   Am. J. Physiol. 276:F122-F128(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND TISSUE SPECIFICITY.
RC   TISSUE=Kidney;
RX   PubMed=9950961;
RA   Lu R., Chan B.S., Schuster V.L.;
RT   "Cloning of the human kidney PAH transporter: narrow substrate
RT   specificity and regulation by protein kinase C.";
RL   Am. J. Physiol. 276:F295-F303(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND TISSUE SPECIFICITY.
RC   TISSUE=Kidney;
RX   PubMed=10049739; DOI=10.1006/bbrc.1998.9978;
RA   Race J.E., Grassl S.M., Williams W.J., Holtzman E.J.;
RT   "Molecular cloning and characterization of two novel human renal
RT   organic anion transporters (hOAT1 and hOAT3).";
RL   Biochem. Biophys. Res. Commun. 255:508-514(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), GLYCOSYLATION,
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND TISSUE SPECIFICITY.
RC   TISSUE=Kidney;
RX   PubMed=10462545;
RA   Cihlar T., Lin D.C., Pritchard J.B., Fuller M.D., Mendel D.B.,
RA   Sweet D.H.;
RT   "The antiviral nucleotide analogs cidofovir and adefovir are novel
RT   substrates for human and rat renal organic anion transporter 1.";
RL   Mol. Pharmacol. 56:570-580(1999).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 3 AND 4),
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND TISSUE SPECIFICITY.
RC   TISSUE=Kidney;
RX   PubMed=10964714; DOI=10.1006/bbrc.2000.3230;
RA   Bahn A., Prawitt D., Buttler D., Reid G., Enklaar T., Wolff N.A.,
RA   Ebbinghaus C., Hillemann A., Schulten H.-J., Gunawan B., Fuezesi L.,
RA   Zabel B., Burckhardt G.;
RT   "Genomic structure and in vivo expression of the human organic anion
RT   transporter 1 (hOAT1) gene.";
RL   Biochem. Biophys. Res. Commun. 275:623-630(2000).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LEU-104.
RG   NIEHS SNPs program;
RL   Submitted (MAR-2008) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=12538807; DOI=10.1124/jpet.102.043455;
RA   Groves C.E., Munoz L., Bahn A., Burckhardt G., Wright S.H.;
RT   "Interaction of cysteine conjugates with human and rabbit organic
RT   anion transporter 1.";
RL   J. Pharmacol. Exp. Ther. 304:560-566(2003).
RN   [12]
RP   MUTAGENESIS OF ASN-39, AND GLYCOSYLATION AT ASN-39; ASN-56; ASN-92 AND
RP   ASN-97.
RX   PubMed=14749323; DOI=10.1074/jbc.M400197200;
RA   Tanaka K., Xu W., Zhou F., You G.;
RT   "Role of glycosylation in the organic anion transporter OAT1.";
RL   J. Biol. Chem. 279:14961-14966(2004).
RN   [13]
RP   MUTAGENESIS OF LEU-30 AND THR-36.
RX   PubMed=15145940; DOI=10.1074/jbc.M404686200;
RA   Hong M., Zhou F., You G.;
RT   "Critical amino acid residues in transmembrane domain 1 of the human
RT   organic anion transporter hOAT1.";
RL   J. Biol. Chem. 279:31478-31482(2004).
RN   [14]
RP   FUNCTION.
RX   PubMed=15644426; DOI=10.1124/jpet.104.080366;
RA   Srimaroeng C., Chatsudthipong V., Aslamkhan A.G., Pritchard J.B.;
RT   "Transport of the natural sweetener stevioside and its aglycone
RT   steviol by human organic anion transporter (hOAT1; SLC22A6) and hOAT3
RT   (SLC22A8).";
RL   J. Pharmacol. Exp. Ther. 313:621-628(2005).
RN   [15]
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=15846473; DOI=10.1007/s11095-005-2503-0;
RA   Tahara H., Shono M., Kusuhara H., Kinoshita H., Fuse E., Takadate A.,
RA   Otagiri M., Sugiyama Y.;
RT   "Molecular cloning and functional analyses of OAT1 and OAT3 from
RT   cynomolgus monkey kidney.";
RL   Pharm. Res. 22:647-660(2005).
RN   [16]
RP   MUTAGENESIS OF TYR-230; LYS-431 AND PHE-438, SUBSTRATE-BINDING SITES,
RP   AND FUNCTION.
RX   PubMed=17038320; DOI=10.1074/jbc.M608834200;
RA   Perry J.L., Dembla-Rajpal N., Hall L.A., Pritchard J.B.;
RT   "A three-dimensional model of human organic anion transporter 1:
RT   aromatic amino acids required for substrate transport.";
RL   J. Biol. Chem. 281:38071-38079(2006).
RN   [17]
RP   FUNCTION.
RX   PubMed=17502342; DOI=10.1124/dmd.106.013912;
RA   Mizuno N., Takahashi T., Iwase Y., Kusuhara H., Niwa T., Sugiyama Y.;
RT   "Human organic anion transporters 1 (hOAT1/SLC22A6) and 3
RT   (hOAT3/SLC22A8) transport edaravone (MCI-186; 3-methyl-1-phenyl-2-
RT   pyrazolin-5-one) and its sulfate conjugate.";
RL   Drug Metab. Dispos. 35:1429-1434(2007).
RN   [18]
RP   VARIANT HIS-50, AND CHARACTERIZATION OF VARIANT HIS-50.
RX   PubMed=15914676; DOI=10.1124/jpet.105.084301;
RA   Bleasby K., Hall L.A., Perry J.L., Mohrenweiser H.W., Pritchard J.B.;
RT   "Functional consequences of single nucleotide polymorphisms in the
RT   human organic anion transporter hOAT1 (SLC22A6).";
RL   J. Pharmacol. Exp. Ther. 314:923-931(2005).
RN   [19]
RP   VARIANTS PRO-7 AND HIS-50.
RX   PubMed=16164626; DOI=10.1111/j.1523-1755.2005.00612.x;
RA   Xu G., Bhatnagar V., Wen G., Hamilton B.A., Eraly S.A., Nigam S.K.;
RT   "Analyses of coding region polymorphisms in apical and basolateral
RT   human organic anion transporter (OAT) genes [OAT1 (NKT), OAT2, OAT3,
RT   OAT4, URAT (RST)].";
RL   Kidney Int. 68:1491-1499(2005).
CC   -!- FUNCTION: Involved in the renal elimination of endogenous and
CC       exogenous organic anions. Functions as organic anion exchanger
CC       when the uptake of one molecule of organic anion is coupled with
CC       an efflux of one molecule of endogenous dicarboxylic acid
CC       (glutarate, ketoglutarate, etc). Mediates the sodium-independent
CC       uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By
CC       similarity). Mediates the sodium-independent uptake of p-
CC       aminohippurate (PAH), ochratoxin (OTA), acyclovir (ACV), 3'-azido-
CC       3-'deoxythymidine (AZT), cimetidine (CMD), 2,4-dichloro-
CC       phenoxyacetate (2,4-D), hippurate (HA), indoleacetate (IA),
CC       indoxyl sulfate (IS) and 3-carboxy-4-methyl-5-propyl-2-
CC       furanpropionate (CMPF), cidofovir, adefovir, 9-(2-
CC       phosphonylmethoxyethyl) guanine (PMEG), 9-(2-
CC       phosphonylmethoxyethyl) diaminopurine (PMEDAP) and edaravone
CC       sulfate. PAH uptake is inhibited by p-
CC       chloromercuribenzenesulphonate (PCMBS), diethyl pyrocarbonate
CC       (DEPC), sulindac, diclofenac, carprofen, glutarate and okadaic
CC       acid (By similarity). PAH uptake is inhibited by
CC       benzothiazolylcysteine (BTC), S-chlorotrifluoroethylcysteine
CC       (CTFC), cysteine S-conjugates S-dichlorovinylcysteine (DCVC),
CC       furosemide, steviol, phorbol 12-myristate 13-acetate (PMA),
CC       calcium ionophore A23187, benzylpenicillin, furosemide,
CC       indomethacin, bumetamide, losartan, probenecid, phenol red, urate,
CC       and alpha-ketoglutarate. {ECO:0000250,
CC       ECO:0000269|PubMed:12538807, ECO:0000269|PubMed:15644426,
CC       ECO:0000269|PubMed:17038320, ECO:0000269|PubMed:17502342,
CC       ECO:0000269|PubMed:9762842, ECO:0000269|PubMed:9887087}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=9.3 uM for PAH (isoform 1) {ECO:0000269|PubMed:10462545,
CC         ECO:0000269|PubMed:10964714, ECO:0000269|PubMed:12538807,
CC         ECO:0000269|PubMed:15846473};
CC         KM=4 uM for PAH (isoform 2) {ECO:0000269|PubMed:10462545,
CC         ECO:0000269|PubMed:10964714, ECO:0000269|PubMed:12538807,
CC         ECO:0000269|PubMed:15846473};
CC         KM=11 uM for edaravone {ECO:0000269|PubMed:10462545,
CC         ECO:0000269|PubMed:10964714, ECO:0000269|PubMed:12538807,
CC         ECO:0000269|PubMed:15846473};
CC         KM=46 uM for cidofovir {ECO:0000269|PubMed:10462545,
CC         ECO:0000269|PubMed:10964714, ECO:0000269|PubMed:12538807,
CC         ECO:0000269|PubMed:15846473};
CC         KM=30 uM for adefovir {ECO:0000269|PubMed:10462545,
CC         ECO:0000269|PubMed:10964714, ECO:0000269|PubMed:12538807,
CC         ECO:0000269|PubMed:15846473};
CC         KM=5.77 uM for 2,4-D {ECO:0000269|PubMed:10462545,
CC         ECO:0000269|PubMed:10964714, ECO:0000269|PubMed:12538807,
CC         ECO:0000269|PubMed:15846473};
CC         KM=23.5 uM for HA {ECO:0000269|PubMed:10462545,
CC         ECO:0000269|PubMed:10964714, ECO:0000269|PubMed:12538807,
CC         ECO:0000269|PubMed:15846473};
CC         KM=14 uM for IA {ECO:0000269|PubMed:10462545,
CC         ECO:0000269|PubMed:10964714, ECO:0000269|PubMed:12538807,
CC         ECO:0000269|PubMed:15846473};
CC         KM=20.5 uM for IS {ECO:0000269|PubMed:10462545,
CC         ECO:0000269|PubMed:10964714, ECO:0000269|PubMed:12538807,
CC         ECO:0000269|PubMed:15846473};
CC         KM=141 uM for CMPF {ECO:0000269|PubMed:10462545,
CC         ECO:0000269|PubMed:10964714, ECO:0000269|PubMed:12538807,
CC         ECO:0000269|PubMed:15846473};
CC         Vmax=534 pmol/min/mg enzyme for 2,4-D uptake
CC         {ECO:0000269|PubMed:10462545, ECO:0000269|PubMed:10964714,
CC         ECO:0000269|PubMed:12538807, ECO:0000269|PubMed:15846473};
CC         Vmax=430 pmol/min/mg enzyme for HA uptake
CC         {ECO:0000269|PubMed:10462545, ECO:0000269|PubMed:10964714,
CC         ECO:0000269|PubMed:12538807, ECO:0000269|PubMed:15846473};
CC         Vmax=110 pmol/min/mg enzyme for IA uptake
CC         {ECO:0000269|PubMed:10462545, ECO:0000269|PubMed:10964714,
CC         ECO:0000269|PubMed:12538807, ECO:0000269|PubMed:15846473};
CC         Vmax=216 pmol/min/mg enzyme for IS uptake
CC         {ECO:0000269|PubMed:10462545, ECO:0000269|PubMed:10964714,
CC         ECO:0000269|PubMed:12538807, ECO:0000269|PubMed:15846473};
CC         Vmax=801 pmol/min/mg enzyme for CMPF uptake
CC         {ECO:0000269|PubMed:10462545, ECO:0000269|PubMed:10964714,
CC         ECO:0000269|PubMed:12538807, ECO:0000269|PubMed:15846473};
CC   -!- INTERACTION:
CC       Q92624:APPBP2; NbExp=3; IntAct=EBI-749741, EBI-743771;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305}; Multi-pass
CC       membrane protein {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=OAT1-1;
CC         IsoId=Q4U2R8-1; Sequence=Displayed;
CC       Name=2; Synonyms=OAT1-2;
CC         IsoId=Q4U2R8-2; Sequence=VSP_032169;
CC       Name=3; Synonyms=OAT1-3;
CC         IsoId=Q4U2R8-3; Sequence=VSP_032168, VSP_032169;
CC         Note=No experimental confirmation available.;
CC       Name=4; Synonyms=OAT1-4;
CC         IsoId=Q4U2R8-4; Sequence=VSP_032168;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Strongly expressed in kidney and to a lower
CC       extent in liver, skeletal muscle, brain and placenta. Found at the
CC       basolateral membrane of the proximal tubule.
CC       {ECO:0000269|PubMed:10049739, ECO:0000269|PubMed:10462545,
CC       ECO:0000269|PubMed:10964714, ECO:0000269|PubMed:9887087,
CC       ECO:0000269|PubMed:9950961}.
CC   -!- DOMAIN: Multiple cysteine residues are necessary for proper
CC       targeting to the plasma membrane. {ECO:0000250}.
CC   -!- PTM: Glycosylated. Glycosylation at Asn-113 may occur at a
CC       secondary level. Glycosylation is necessary for proper targeting
CC       of the transporter to the plasma membrane.
CC       {ECO:0000269|PubMed:10462545, ECO:0000269|PubMed:14749323}.
CC   -!- SIMILARITY: Belongs to the major facilitator (TC 2.A.1)
CC       superfamily. Organic cation transporter (TC 2.A.1.19) family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/slc22a6/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF057039; AAC70004.1; -; mRNA.
DR   EMBL; AB009697; BAA75072.1; -; mRNA.
DR   EMBL; AB009698; BAA75073.1; -; mRNA.
DR   EMBL; AF104038; AAD10052.1; -; mRNA.
DR   EMBL; AF097490; AAD19356.1; -; mRNA.
DR   EMBL; AF124373; AAD55356.1; -; mRNA.
DR   EMBL; AJ249369; CAB77184.1; -; Genomic_DNA.
DR   EMBL; AJ251529; CAB94830.1; -; mRNA.
DR   EMBL; AJ271205; CAB97249.1; -; mRNA.
DR   EMBL; EU567146; ACB21049.1; -; Genomic_DNA.
DR   EMBL; AP001858; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471076; EAW74129.1; -; Genomic_DNA.
DR   EMBL; CH471076; EAW74130.1; -; Genomic_DNA.
DR   EMBL; CH471076; EAW74131.1; -; Genomic_DNA.
DR   EMBL; CH471076; EAW74132.1; -; Genomic_DNA.
DR   EMBL; BC033682; AAH33682.1; -; mRNA.
DR   CCDS; CCDS31591.1; -. [Q4U2R8-1]
DR   CCDS; CCDS44631.1; -. [Q4U2R8-4]
DR   CCDS; CCDS44632.1; -. [Q4U2R8-3]
DR   CCDS; CCDS8041.1; -. [Q4U2R8-2]
DR   RefSeq; NP_004781.2; NM_004790.4. [Q4U2R8-1]
DR   RefSeq; NP_695008.1; NM_153276.2. [Q4U2R8-2]
DR   RefSeq; NP_695009.1; NM_153277.2. [Q4U2R8-3]
DR   RefSeq; NP_695010.1; NM_153278.2. [Q4U2R8-4]
DR   UniGene; Hs.369252; -.
DR   ProteinModelPortal; Q4U2R8; -.
DR   BioGrid; 114759; 20.
DR   IntAct; Q4U2R8; 2.
DR   MINT; MINT-1474237; -.
DR   STRING; 9606.ENSP00000367102; -.
DR   BindingDB; Q4U2R8; -.
DR   ChEMBL; CHEMBL1641347; -.
DR   DrugBank; DB00316; Acetaminophen.
DR   DrugBank; DB00819; Acetazolamide.
DR   DrugBank; DB06151; Acetylcysteine.
DR   DrugBank; DB00945; Acetylsalicylic acid.
DR   DrugBank; DB00787; Aciclovir.
DR   DrugBank; DB00718; Adefovir Dipivoxil.
DR   DrugBank; DB00345; Aminohippuric acid.
DR   DrugBank; DB01424; Aminophenazone.
DR   DrugBank; DB01060; Amoxicillin.
DR   DrugBank; DB01435; Antipyrine.
DR   DrugBank; DB00168; Aspartame.
DR   DrugBank; DB01053; Benzylpenicillin.
DR   DrugBank; DB01237; Bromodiphenhydramine.
DR   DrugBank; DB00887; Bumetanide.
DR   DrugBank; DB04519; Caprylic acid.
DR   DrugBank; DB01197; Captopril.
DR   DrugBank; DB00578; Carbenicillin.
DR   DrugBank; DB00821; Carprofen.
DR   DrugBank; DB00520; Caspofungin.
DR   DrugBank; DB01414; Cefacetrile.
DR   DrugBank; DB01140; Cefadroxil.
DR   DrugBank; DB00456; Cefalotin.
DR   DrugBank; DB01326; Cefamandole.
DR   DrugBank; DB01327; Cefazolin.
DR   DrugBank; DB01329; Cefoperazone.
DR   DrugBank; DB00493; Cefotaxime.
DR   DrugBank; DB00229; Cefotiam.
DR   DrugBank; DB01333; Cefradine.
DR   DrugBank; DB00438; Ceftazidime.
DR   DrugBank; DB01212; Ceftriaxone.
DR   DrugBank; DB00567; Cephalexin.
DR   DrugBank; DB00446; Chloramphenicol.
DR   DrugBank; DB00880; Chlorothiazide.
DR   DrugBank; DB00672; Chlorpropamide.
DR   DrugBank; DB00369; Cidofovir.
DR   DrugBank; DB01597; Cilastatin.
DR   DrugBank; DB00501; Cimetidine.
DR   DrugBank; DB00827; Cinoxacin.
DR   DrugBank; DB01147; Cloxacillin.
DR   DrugBank; DB00286; Conjugated Equine Estrogens.
DR   DrugBank; DB02527; Cyclic Adenosine Monophosphate.
DR   DrugBank; DB02315; Cyclic Guanosine Monophosphate.
DR   DrugBank; DB00091; Cyclosporine.
DR   DrugBank; DB00606; Cyclothiazide.
DR   DrugBank; DB08912; Dabrafenib.
DR   DrugBank; DB04133; Degraded Cephaloridine.
DR   DrugBank; DB00586; Diclofenac.
DR   DrugBank; DB00900; Didanosine.
DR   DrugBank; DB00861; Diflunisal.
DR   DrugBank; DB01160; Dinoprost Tromethamine.
DR   DrugBank; DB00917; Dinoprostone.
DR   DrugBank; DB00254; Doxycycline.
DR   DrugBank; DB08846; Ellagic Acid.
DR   DrugBank; DB00584; Enalapril.
DR   DrugBank; DB00903; Etacrynic acid.
DR   DrugBank; DB00311; Ethoxzolamide.
DR   DrugBank; DB00749; Etodolac.
DR   DrugBank; DB02266; Flufenamic Acid.
DR   DrugBank; DB00693; Fluorescein.
DR   DrugBank; DB00712; Flurbiprofen.
DR   DrugBank; DB00158; Folic Acid.
DR   DrugBank; DB00529; Foscarnet.
DR   DrugBank; DB00695; Furosemide.
DR   DrugBank; DB01004; Ganciclovir.
DR   DrugBank; DB00798; Gentamicin.
DR   DrugBank; DB03553; Glutaric Acid.
DR   DrugBank; DB01016; Glyburide.
DR   DrugBank; DB00365; Grepafloxacin.
DR   DrugBank; DB00999; Hydrochlorothiazide.
DR   DrugBank; DB01050; Ibuprofen.
DR   DrugBank; DB00328; Indomethacin.
DR   DrugBank; DB01009; Ketoprofen.
DR   DrugBank; DB00709; Lamivudine.
DR   DrugBank; DB01137; Levofloxacin.
DR   DrugBank; DB00678; Losartan.
DR   DrugBank; DB00939; Meclofenamic acid.
DR   DrugBank; DB00703; Methazolamide.
DR   DrugBank; DB00563; Methotrexate.
DR   DrugBank; DB01017; Minocycline.
DR   DrugBank; DB00607; Nafcillin.
DR   DrugBank; DB00779; Nalidixic Acid.
DR   DrugBank; DB00788; Naproxen.
DR   DrugBank; DB00731; Nateglinide.
DR   DrugBank; DB01059; Norfloxacin.
DR   DrugBank; DB01051; Novobiocin.
DR   DrugBank; DB01165; Ofloxacin.
DR   DrugBank; DB03585; Oxyphenbutazone.
DR   DrugBank; DB00595; Oxytetracycline.
DR   DrugBank; DB03783; Phenacetin.
DR   DrugBank; DB00812; Phenylbutazone.
DR   DrugBank; DB00319; Piperacillin.
DR   DrugBank; DB00554; Piroxicam.
DR   DrugBank; DB00175; Pravastatin.
DR   DrugBank; DB01032; Probenecid.
DR   DrugBank; DB00140; Riboflavin.
DR   DrugBank; DB00936; Salicylic acid.
DR   DrugBank; DB00649; Stavudine.
DR   DrugBank; DB01082; Streptomycin.
DR   DrugBank; DB00605; Sulindac.
DR   DrugBank; DB04348; Taurocholic Acid.
DR   DrugBank; DB00300; Tenofovir.
DR   DrugBank; DB00759; Tetracycline.
DR   DrugBank; DB01124; Tolbutamide.
DR   DrugBank; DB00500; Tolmetin.
DR   DrugBank; DB00432; Trifluridine.
DR   DrugBank; DB08844; Uric Acid.
DR   DrugBank; DB00577; Valaciclovir.
DR   DrugBank; DB00313; Valproic Acid.
DR   DrugBank; DB00512; Vancomycin.
DR   DrugBank; DB00943; Zalcitabine.
DR   DrugBank; DB00495; Zidovudine.
DR   GuidetoPHARMACOLOGY; 1025; -.
DR   TCDB; 2.A.1.19.31; the major facilitator superfamily (mfs).
DR   iPTMnet; Q4U2R8; -.
DR   PhosphoSitePlus; Q4U2R8; -.
DR   BioMuta; SLC22A6; -.
DR   DMDM; 74762955; -.
DR   EPD; Q4U2R8; -.
DR   PaxDb; Q4U2R8; -.
DR   PeptideAtlas; Q4U2R8; -.
DR   PRIDE; Q4U2R8; -.
DR   DNASU; 9356; -.
DR   Ensembl; ENST00000360421; ENSP00000353597; ENSG00000197901. [Q4U2R8-2]
DR   Ensembl; ENST00000377871; ENSP00000367102; ENSG00000197901. [Q4U2R8-1]
DR   Ensembl; ENST00000421062; ENSP00000404441; ENSG00000197901. [Q4U2R8-4]
DR   Ensembl; ENST00000458333; ENSP00000396401; ENSG00000197901. [Q4U2R8-3]
DR   GeneID; 9356; -.
DR   KEGG; hsa:9356; -.
DR   UCSC; uc001nwj.4; human. [Q4U2R8-1]
DR   CTD; 9356; -.
DR   DisGeNET; 9356; -.
DR   GeneCards; SLC22A6; -.
DR   HGNC; HGNC:10970; SLC22A6.
DR   MIM; 607582; gene.
DR   neXtProt; NX_Q4U2R8; -.
DR   OpenTargets; ENSG00000197901; -.
DR   PharmGKB; PA388; -.
DR   eggNOG; KOG0255; Eukaryota.
DR   eggNOG; COG0477; LUCA.
DR   GeneTree; ENSGT00760000118852; -.
DR   HOVERGEN; HBG108433; -.
DR   InParanoid; Q4U2R8; -.
DR   KO; K08203; -.
DR   OMA; MIRQTGM; -.
DR   OrthoDB; EOG091G07CO; -.
DR   PhylomeDB; Q4U2R8; -.
DR   TreeFam; TF315847; -.
DR   Reactome; R-HSA-561048; Organic anion transport.
DR   GeneWiki; Organic_anion_transporter_1; -.
DR   GenomeRNAi; 9356; -.
DR   PRO; PR:Q4U2R8; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000197901; -.
DR   ExpressionAtlas; Q4U2R8; baseline and differential.
DR   Genevisible; Q4U2R8; HS.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005901; C:caveola; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043234; C:protein complex; IEA:Ensembl.
DR   GO; GO:0015301; F:anion:anion antiporter activity; TAS:Reactome.
DR   GO; GO:0031404; F:chloride ion binding; IEA:Ensembl.
DR   GO; GO:0005452; F:inorganic anion exchanger activity; IDA:UniProtKB.
DR   GO; GO:0008514; F:organic anion transmembrane transporter activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IEA:Ensembl.
DR   GO; GO:0015347; F:sodium-independent organic anion transmembrane transporter activity; IDA:UniProtKB.
DR   GO; GO:0015143; F:urate transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0015742; P:alpha-ketoglutarate transport; IDA:UniProtKB.
DR   GO; GO:0015711; P:organic anion transport; IDA:UniProtKB.
DR   GO; GO:0051260; P:protein homooligomerization; IEA:Ensembl.
DR   GO; GO:0097254; P:renal tubular secretion; IMP:UniProtKB.
DR   GO; GO:0031427; P:response to methotrexate; IEA:Ensembl.
DR   GO; GO:0043252; P:sodium-independent organic anion transport; IDA:UniProtKB.
DR   GO; GO:0015747; P:urate transport; IBA:GO_Central.
DR   CDD; cd06174; MFS; 1.
DR   InterPro; IPR020846; MFS_dom.
DR   InterPro; IPR005828; MFS_sugar_transport-like.
DR   InterPro; IPR004749; Orgcat_transp/SVOP.
DR   Pfam; PF00083; Sugar_tr; 1.
DR   SUPFAM; SSF103473; SSF103473; 1.
DR   TIGRFAMs; TIGR00898; 2A0119; 1.
DR   PROSITE; PS50850; MFS; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Complete proteome; Glycoprotein;
KW   Membrane; Polymorphism; Reference proteome; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN         1    563       Solute carrier family 22 member 6.
FT                                /FTId=PRO_0000324166.
FT   TOPO_DOM      1      9       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     10     30       Helical. {ECO:0000255}.
FT   TOPO_DOM     31    135       Extracellular. {ECO:0000255}.
FT   TRANSMEM    136    156       Helical. {ECO:0000255}.
FT   TOPO_DOM    157    164       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    165    187       Helical. {ECO:0000255}.
FT   TOPO_DOM    188    190       Extracellular. {ECO:0000255}.
FT   TRANSMEM    191    213       Helical. {ECO:0000255}.
FT   TOPO_DOM    214    224       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    225    245       Helical. {ECO:0000255}.
FT   TOPO_DOM    246    248       Extracellular. {ECO:0000255}.
FT   TRANSMEM    249    269       Helical. {ECO:0000255}.
FT   TOPO_DOM    270    337       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    338    358       Helical. {ECO:0000255}.
FT   TOPO_DOM    359    368       Extracellular. {ECO:0000255}.
FT   TRANSMEM    369    389       Helical. {ECO:0000255}.
FT   TOPO_DOM    390    395       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    396    416       Helical. {ECO:0000255}.
FT   TOPO_DOM    417    425       Extracellular. {ECO:0000255}.
FT   TRANSMEM    426    446       Helical. {ECO:0000255}.
FT   TOPO_DOM    447    455       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    456    475       Helical. {ECO:0000255}.
FT   TOPO_DOM    476    484       Extracellular. {ECO:0000255}.
FT   TRANSMEM    485    505       Helical. {ECO:0000255}.
FT   TOPO_DOM    506    563       Cytoplasmic. {ECO:0000255}.
FT   SITE        230    230       Important for interaction with cidofovir.
FT   SITE        438    438       Important for interaction with cidofovir
FT                                and PAH.
FT   CARBOHYD     39     39       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:14749323}.
FT   CARBOHYD     56     56       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:14749323}.
FT   CARBOHYD     92     92       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:14749323}.
FT   CARBOHYD     97     97       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:14749323}.
FT   CARBOHYD    113    113       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:10462545}.
FT   VAR_SEQ     455    498       Missing (in isoform 3 and isoform 4).
FT                                {ECO:0000303|PubMed:10964714}.
FT                                /FTId=VSP_032168.
FT   VAR_SEQ     523    535       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:10049739,
FT                                ECO:0000303|PubMed:10462545,
FT                                ECO:0000303|PubMed:10964714,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:9762842,
FT                                ECO:0000303|PubMed:9887087,
FT                                ECO:0000303|PubMed:9950961}.
FT                                /FTId=VSP_032169.
FT   VARIANT       7      7       L -> P. {ECO:0000269|PubMed:16164626}.
FT                                /FTId=VAR_039682.
FT   VARIANT      50     50       R -> H (lower Vmax; increase in substrate
FT                                affinity and increase in the affinity for
FT                                the nucleoside phosphonate analogs
FT                                cidofovir, adefovir and tenofovir;
FT                                dbSNP:rs11568626).
FT                                {ECO:0000269|PubMed:15914676,
FT                                ECO:0000269|PubMed:16164626}.
FT                                /FTId=VAR_039683.
FT   VARIANT     104    104       P -> L (in dbSNP:rs11568627).
FT                                {ECO:0000269|Ref.7}.
FT                                /FTId=VAR_047878.
FT   VARIANT     293    293       R -> W (increase in substrate affinity;
FT                                dbSNP:rs45607933).
FT                                /FTId=VAR_039684.
FT   MUTAGEN      30     30       L->A: Complete loss of PAH transport
FT                                activity. {ECO:0000269|PubMed:15145940}.
FT   MUTAGEN      36     36       T->A: Complete loss of PAH transport
FT                                activity. {ECO:0000269|PubMed:15145940}.
FT   MUTAGEN      39     39       N->Q: Complete loss of PAH transport
FT                                activity. {ECO:0000269|PubMed:14749323}.
FT   MUTAGEN     230    230       Y->A: Loss of membrane protein expression
FT                                and little uptake of cidofovir.
FT                                {ECO:0000269|PubMed:17038320}.
FT   MUTAGEN     431    431       K->A: Decrease in the level of membrane
FT                                protein expression and 70 % loss of PAH
FT                                uptake. {ECO:0000269|PubMed:17038320}.
FT   MUTAGEN     438    438       F->A: Decrease in the level of membrane
FT                                protein expression, 70 % loss of PAH
FT                                uptake, increased affinity for cidofovir,
FT                                lower Vmax for PAH, and lower Km and Vmax
FT                                for cidofovir.
FT                                {ECO:0000269|PubMed:17038320}.
FT   CONFLICT     14     14       G -> S (in Ref. 3; AAD10052).
FT                                {ECO:0000305}.
FT   CONFLICT    563    563       L -> F (in Ref. 1; AAC70004).
FT                                {ECO:0000305}.
SQ   SEQUENCE   563 AA;  61816 MW;  74AD3EA2678032E4 CRC64;
     MAFNDLLQQV GGVGRFQQIQ VTLVVLPLLL MASHNTLQNF TAAIPTHHCR PPADANLSKN
     GGLEVWLPRD RQGQPESCLR FTSPQWGLPF LNGTEANGTG ATEPCTDGWI YDNSTFPSTI
     VTEWDLVCSH RALRQLAQSL YMVGVLLGAM VFGYLADRLG RRKVLILNYL QTAVSGTCAA
     FAPNFPIYCA FRLLSGMALA GISLNCMTLN VEWMPIHTRA CVGTLIGYVY SLGQFLLAGV
     AYAVPHWRHL QLLVSAPFFA FFIYSWFFIE SARWHSSSGR LDLTLRALQR VARINGKREE
     GAKLSMEVLR ASLQKELTMG KGQASAMELL RCPTLRHLFL CLSMLWFATS FAYYGLVMDL
     QGFGVSIYLI QVIFGAVDLP AKLVGFLVIN SLGRRPAQMA ALLLAGICIL LNGVIPQDQS
     IVRTSLAVLG KGCLAASFNC IFLYTGELYP TMIRQTGMGM GSTMARVGSI VSPLVSMTAE
     LYPSMPLFIY GAVPVAASAV TVLLPETLGQ PLPDTVQDLE SRWAPTQKEA GIYPRKGKQT
     RQQQEHQKYM VPLQASAQEK NGL
//
